CISATRACURIUM PFIZER cisatracurium (as besilate) 20 mg/10 mL solution for injection ampoule

国: オーストラリア

言語: 英語

ソース: Department of Health (Therapeutic Goods Administration)

有効成分:

cisatracurium besilate

から入手可能:

Pfizer Australia Pty Ltd

INN（国際名）:

cisatracurium besilate

認証ステータス:

Registered

製品の特徴

Version: pfpcisai10713
Supersedes: pfpcisai10213
Page 1 of 16
PRODUCT INFORMATION
CISATRACURIUM PFIZER

CISATRACURIUM BESYLATE
NAME OF THE MEDICINE
The chemical name of cisatracurium besylate is
(1R,1’R,2R,2’R,)-2,2’-(3,11-dioxo-4,10-
dioxatridecamethylene) bis
(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-
veratrylisoquinolinium) dibenzenesulfonate.
The molecular formula of cisatracurium besylate is C
65
H
82
N
2
O
18
S
2
and it has a molecular
weight of 1243.5. The structural formula is given below:
CAS NUMBER: 96946-42-8
DESCRIPTION
Cisatracurium besylate is a white to pale yellow powder.
CISATRACURIUM PFIZER is supplied in a concentration of 2.68 mg/mL
cisatracurium
besylate, equivalent to cisatracurium 2 mg/mL. CISATRACURIUM PFIZER
also contains
Water for Injections and benzenesulfonic acid.
CISATRACURIUM PFIZER does not contain any preservative and is for
single use in one
patient only. Discard any residue.
PHARMACOLOGY
PHARMACODYNAMICS
Cisatracurium besylate, a stereoisomer of atracurium, is an
intermediate duration, non-
depolarising benzylisoquinolinium skeletal muscle relaxant.
Cisatracurium besylate binds to
Version: pfpcisai10713
Supersedes: pfpcisai10213
Page 2 of 16
cholinergic receptors on the motor end-plate to antagonise the action
of acetylcholine,
resulting in a competitive block of neuromuscular transmission. This
action is readily
reversed by anticholinesterase agents such as neostigmine.
The ED
95
(dose required to produce 95% depression of the twitch response of the
adductor
pollicis muscle to stimulation of the ulnar nerve) of cisatracurium
besylate is estimated to be
0.05 mg/kg bodyweight during opioid anaesthesia (thiopentone,
fentanyl, midazolam). The
recommended intubation dose for cisatracurium besylate in adults is 3
× ED
95
, which has a
longer clinically effective duration than the recommended intubation
dose of atracurium (2 ×
ED
95
) (see DOSAGE AND ADMINISTRATION).
The ED
95
of cisatracurium besylate in children during halothane anaesthesia is
0.04 mg/kg
bodyweight.
Ci